Insights from Pim1 structure for anti-cancer drug design

Bibliography

• Cuypers HT, Selten G, Quint W, Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:141-50
   PubMed Web of Science ®Google Scholar
• van der Lugt NM, Domen J, Verhoeven E, Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-44
   PubMed Web of Science ®Google Scholar
• Feldman JD, Vician L, Crispino M, KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998;273:16535-43
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011;11:23-34
   PubMed Web of Science ®Google Scholar
• Brault L, Gasser C, Bracher F, PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010;95:1004-15
   PubMed Web of Science ®Google Scholar
• Merkel AL, Meggers E, Ocker M. PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drugs 2012;21:425-36
   PubMed Web of Science ®Google Scholar
• Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005;37:726-30
   PubMed Web of Science ®Google Scholar
• Dautry F, Weil D, Yu J, Dautry-Varsat A. Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem 1988;263:17615-20
   PubMed Web of Science ®Google Scholar
• Lilly M, Le T, Holland P, Hendrickson SL. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene 1992;7:727-32
   PubMed Web of Science ®Google Scholar
• Mui AL, Wakao H, Kinoshita T, Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J 1996;15:2425-33
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Weaver M, Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001;2:167-79
   PubMedGoogle Scholar
• Chen XP, Losman JA, Cowan S, Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002;99:2175-80
   PubMed Web of Science ®Google Scholar
• Peltola KJ, Paukku K, Aho TL, Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004;103:3744-50
   PubMed Web of Science ®Google Scholar
• Mizuno K, Shirogane T, Shinohara A, Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 2001;281:663-9
   PubMed Web of Science ®Google Scholar
• Shay KP, Wang Z, Xing PX, Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 2005;3:170-81
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008;27:4809-19
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Mixter PF, Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002;1593:45-55
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007;5:909-22
   PubMed Web of Science ®Google Scholar
• Morishita D, Katayama R, Sekimizu K, Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008;68:5076-85
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Kitanaka C, Noguchi K, Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999;274:18659-66
   PubMed Web of Science ®Google Scholar
• Bachmann M, Hennemann H, Xing PX, The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004;279:48319-28
   PubMed Web of Science ®Google Scholar
• Bachmann M, Kosan C, Xing PX, The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006;38:430-43
   PubMed Web of Science ®Google Scholar
• Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007;9:932-44
   PubMed Web of Science ®Google Scholar
• Fox CJ, Hammerman PS, Cinalli RM, The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003;17:1841-54
   PubMed Web of Science ®Google Scholar
• Chen WW, Chan DC, Donald C, Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005;3:443-51
   PubMed Web of Science ®Google Scholar
• Yan B, Zemskova M, Holder S, The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-67
   PubMed Web of Science ®Google Scholar
• Aho TL, Sandholm J, Peltola KJ, Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-9
   PubMed Web of Science ®Google Scholar
• Xie Y, Xu K, Linn DE, The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 2008;283:3349-56
   PubMed Web of Science ®Google Scholar
• Zhou XM, Liu Y, Payne G, Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. J Biol Chem 2000;275:25046-51
   PubMed Web of Science ®Google Scholar
• Hirai I, Wang HG. Survival-factor-induced phosphorylation of bad results in its dissociation from Bcl-x(L) but not Bcl-2. Biochem J 2001;359:345-52
   PubMed Web of Science ®Google Scholar
• Chao DT, Linette GP, Boise LH, Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995;182:821-8
   PubMed Web of Science ®Google Scholar
• Yang E, Zha J, Jockel J, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91
   PubMed Web of Science ®Google Scholar
• Hogan C, Hutchison C, Marcar L, Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem 2008;283:18012-23
   PubMed Web of Science ®Google Scholar
• Chiocchetti A, Gibello L, Carando A, Interactions between RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein. Haematologica 2005;90:1453-62
   Google Scholar
• Iadevaia V, Caldarola S, Biondini L, PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression. Oncogene 2010;29:5490-9
   Google Scholar
• Amson R, Sigaux F, Przedborski S, The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989;86:8857-61
   PubMed Web of Science ®Google Scholar
• Dhanasekaran SM, Barrette TR, Ghosh D, Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6
   PubMed Web of Science ®Google Scholar
• Domen J, van der Lugt NM, Laird PW, Analysis of Pim-1 function in mutant mice. Leukemia 1993;7(Suppl 2):S108-12
   PubMed Web of Science ®Google Scholar
• Verbeek S, van Lohuizen M, van der Valk M, Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991;11:1176-9
   PubMed Web of Science ®Google Scholar
• Laird PW, van der Lugt NM, Clarke A, In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 1993;21:4750-5
   PubMed Web of Science ®Google Scholar
• Muraski JA, Rota M, Misao Y, Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 2007;13:1467-75
   PubMed Web of Science ®Google Scholar
• Mellor HR, Bell AR, Valentin JP, Roberts RR. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011;120:14-32
   PubMed Web of Science ®Google Scholar
• Hu XF, Li J, Vandervalk S, PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 2009;119:362-75
   PubMed Web of Science ®Google Scholar
• Wang J, Anderson PD, Luo W, Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 2012;31:1794-803
   PubMed Web of Science ®Google Scholar
• Shah N, Pang B, Yeoh KG, Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 2008;44:2144-51
   PubMed Web of Science ®Google Scholar
• Mumenthaler SM, Ng PY, Hodge A, Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 2009;8:2882-93
   PubMed Web of Science ®Google Scholar
• Beharry Z, Zemskova M, Mahajan S, Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009;8:1473-83
   PubMed Web of Science ®Google Scholar
• Pogacic V, Bullock AN, Fedorov O, Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007;67:6916-24
   PubMed Web of Science ®Google Scholar
• Bullock AN, Debreczeni J, Amos AL, Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005;280:41675-82
   PubMed Web of Science ®Google Scholar
• Jacobs MD, Black J, Futer O, Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005;280:13728-34
   PubMed Web of Science ®Google Scholar
• Kumar A, Mandiyan V, Suzuki Y, Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-93
   PubMed Web of Science ®Google Scholar
• Qian KC, Wang L, Hickey ER, Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005;280:6130-7
   PubMed Web of Science ®Google Scholar
• Cheney IW, Yan S, Appleby T, Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007;17:1679-83
   PubMed Web of Science ®Google Scholar
• Holder S, Zemskova M, Zhang C, Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-72
   PubMed Web of Science ®Google Scholar
• Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007;13:2751-65
   PubMed Web of Science ®Google Scholar
• Anastassiadis T, Deacon SW, Devarajan K, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1039-45
   PubMed Web of Science ®Google Scholar
• Schenone S, Tintori C, Botta M. Using insights into Pim1 structure to design new anticancer drugs. Curr Pharm Des 2010;16:3964-78
   PubMed Web of Science ®Google Scholar
• Tsuganezawa K, Watanabe H, Parker L, A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide. J Mol Biol 2012;417:240-52
   PubMed Web of Science ®Google Scholar
• Olla S, Manetti F, Crespan E, Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. Bioorg Med Chem Lett 2009;19:1512-16
   PubMed Web of Science ®Google Scholar
• Hall MD, Salam NK, Hellawell JL, Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem 2009;52:3191-204
   PubMed Web of Science ®Google Scholar
• Fedorov O, Marsden B, Pogacic V, A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007;104:20523-8
   PubMed Web of Science ®Google Scholar
• Nishiguchi GA, Atallah G, Bellamacina C, Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases. Bioorg Med Chem Lett 2011;21:6366-9
   PubMed Web of Science ®Google Scholar
• Pierre F, Stefan E, Nedellec AS, 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 2011;21:6687-92
   PubMed Web of Science ®Google Scholar
• Forshell LP, Li Y, Forshell TZ, The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget 2011;2:448-60
   Google Scholar
• Tao ZF, Hasvold LA, Leverson JD, Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM) kinases. J Med Chem 2009;52:6621-36
   PubMed Web of Science ®Google Scholar
• Mikkers H, Nawijn M, Allen J, Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-15
   PubMed Web of Science ®Google Scholar
• Maksimoska J, Williams DS, Atilla-Gokcumen GE, Similar biological activities of two isostructural ruthenium and osmium complexes. Chemistry 2008;14:4816-22
   PubMed Web of Science ®Google Scholar
• Debreczeni JE, Bullock AN, Atilla GE, Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl 2006;45:1580-5
   PubMed Web of Science ®Google Scholar
• Bregman H, Carroll PJ, Meggers E. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J Am Chem Soc 2006;128:877-84
   PubMed Web of Science ®Google Scholar
• Feng L, Geisselbrecht Y, Blanck S, Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 2011;133:5976-86
   PubMed Web of Science ®Google Scholar
• Friedmann M, Nissen MS, Hoover DS, Characterization of the proto-oncogene pim-1: kinase activity and substrate recognition sequence. Arch Biochem Biophys 1992;298:594-601
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998;273:11987-90
   PubMed Web of Science ®Google Scholar
• Kobe B, Kemp BE. Active site-directed protein regulation. Nature 1999;402:373-6
   PubMed Web of Science ®Google Scholar
• Bullock AN, Debreczeni JE, Fedorov OY, Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005;48:7604-14
   PubMed Web of Science ®Google Scholar
• Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem 2008;51:1972-5
   PubMed Web of Science ®Google Scholar
• Qian K, Wang L, Cywin CL, Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009;52:1814-27
   PubMed Web of Science ®Google Scholar
• Akue-Gedu R, Rossignol E, Azzaro S, Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009;52:6369-81
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Bearss D, Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009;114:4150-7
   PubMed Web of Science ®Google Scholar
• Chen LS, Redkar S, Taverna P, Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood 2011;118:693-702
   PubMed Web of Science ®Google Scholar
• Chang M, Kanwar N, Feng E, PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther 2010;9:2478-87
   PubMed Web of Science ®Google Scholar
• Siu A, Virtanen C, Jongstra J. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget 2011;2:1134-44
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Espitia CM, Medina EC, Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Br J Cancer 2011;105:1563-73
   PubMed Web of Science ®Google Scholar
• Kelly KR, Espitia CM, Taverna P, Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol 2012;156:129-32
   PubMed Web of Science ®Google Scholar
• Hospital MA, Green AS, Lacombe C, The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. Blood 2012;119:1791-2
   PubMed Web of Science ®Google Scholar
• Foulks JM, Xu Y, Senina A, Second generation PIM inhibitor exhibits potent activity in tumor models. The 103rd Annual Meeting of the American Association for Cancer Research; March 31 – April 4 2012; Chicago, IL. Philadelphia (PA)
   Google Scholar
• Grey R, Pierce AC, Bemis GW, Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2009;19:3019-22
   PubMed Web of Science ®Google Scholar
• Shafer CM, Lindvall M, Bellamacina C, 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 2008;18:4482-5
   PubMed Web of Science ®Google Scholar
• Parker LJ, Watanabe H, Tsuganezawa K, Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor. Acta Crystallogr Sect F Struct Biol Cryst Commun 2012;68:860-6
   PubMed Web of Science ®Google Scholar
• Patel RY, Doerksen RJ. Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop. J Proteome Res 2010;9:4433-42
   PubMed Web of Science ®Google Scholar
• Guimaraes CR, Rai BK, Munchhof MJ, Understanding the impact of the P-loop conformation on kinase selectivity. J Chem Inf Model 2011;51:1199-204
   PubMed Web of Science ®Google Scholar
• Huber K, Brault L, Fedorov O, 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem 2012;55:403-13
   PubMed Web of Science ®Google Scholar
• Morishita D, Takami M, Yoshikawa S, Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem 2011;286:2681-8
   PubMed Web of Science ®Google Scholar
• Palaty CK, Clark-Lewis I, Leung D, Pelech SL. Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 1997;75:153-62
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Meyer MK, Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 2001;390:9-18
   PubMed Web of Science ®Google Scholar
• Bhattacharya N, Wang Z, Davitt C, Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 2002;111:80-95
   PubMed Web of Science ®Google Scholar
• Peng C, Knebel A, Morrice NA, Pim kinase substrate identification and specificity. J Biochem 2007;141:353-62
   PubMed Web of Science ®Google Scholar
• Mikuni J, Kato M, Taruya S, A fluorescence correlation spectroscopy-based assay for fragment screening of slowly inhibiting protein-peptide interaction inhibitors. Anal Biochem 2010;402:26-31
   PubMed Web of Science ®Google Scholar
• Nakano H, Saito N, Parker L, Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. J Med Chem 2012;55:5151-64
   PubMed Web of Science ®Google Scholar